摘要
Abstract
Objective To investigate the clinical effect of rituximab monoclonal antibody plus methotrexate on primary central nervous system lymphoma.Methods Fifty-four cases of primary central nervous system lymphoma in this hospital from January 2014 to February 2016 were selected and divided into the control group and observation group according to the random number method,27 cases in each group.The control group adopted the scheme of high-dose methotrexate combined with whole brain radiotherapy,while on this basis the observation group used rituximab monoclonal antibody.Then the curative effects were compared.Re-sults The effective rate of the observation group was higher than that of the control group,the difference was statistically significant(X2= 6.033,P< 0.05).In the comparison of the adverse reactions between the two groups,only one item of respiratory tract infection in the observation group was higher than that in the control group,the difference was statistically significant(P< 0.05),the difference of other adverse reactions had no statistical significance(P>0.05).The quality of life in the observation group was better than that in the con-trol group,the difference was statistically significant(Z= 2.895,P< 0.05).The 1-year survival rate,3-year survival rate and survival time of the observation group were better than those of the control group,the differ-ences were statistically significant(P<0.05).Conclusion Adopting rituximab monoclonal antibody and high-dose methotrexate for treating primary central nervous system lymphoma can improve the treatment effective rate,improves the patient′s living quality and survival rate,and is worth promotion within the clinical scope.关键词
利妥昔单克隆抗体/甲氨蝶呤/淋巴瘤/中枢神经系统Key words
rituximab monoclonal antibody/methotrexate/lymphoma/central nervous system分类
医药卫生
